Heat Biologics, Inc. (HTBX): Price and Financial Metrics


Heat Biologics, Inc. (HTBX): $6.12

-0.15 (-2.39%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add HTBX to Watchlist
Sign Up

Industry: Biotech


Ranked

of 505

in industry

HTBX POWR Grades


  • HTBX scores best on the Value dimension, with a Value rank ahead of 48.19% of US stocks.
  • HTBX's strongest trending metric is Momentum; it's been moving down over the last 48 weeks.
  • HTBX ranks lowest in Quality; there it ranks in the 7th percentile.

HTBX Stock Summary

  • HTBX's price/sales ratio is 64.97; that's higher than the P/S ratio of 95.75% of US stocks.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at 1.06 for Heat Biologics Inc; that's greater than it is for just 6.72% of US stocks.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for HTBX comes in at -65.62% -- higher than that of only 4.1% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Heat Biologics Inc are PI, DCTH, CRNC, WATT, and PACB.
  • Visit HTBX's SEC page to see the company's official filings. To visit the company's web site, go to www.heatbio.com.

HTBX Valuation Summary

  • In comparison to the median Healthcare stock, HTBX's price/sales ratio is 559.91% higher, now standing at 74.9.
  • HTBX's price/earnings ratio has moved up 4 over the prior 97 months.
  • HTBX's EV/EBIT ratio has moved up 10.9 over the prior 97 months.

Below are key valuation metrics over time for HTBX.

Stock Date P/S P/B P/E EV/EBIT
HTBX 2021-08-31 74.9 1.4 -6.2 -5.6
HTBX 2021-08-30 70.7 1.3 -5.9 -5.2
HTBX 2021-08-27 72.0 1.3 -6.0 -5.3
HTBX 2021-08-26 70.1 1.3 -5.8 -5.2
HTBX 2021-08-25 69.7 1.3 -5.8 -5.1
HTBX 2021-08-24 68.9 1.3 -5.7 -5.1

HTBX Growth Metrics

  • Its 2 year price growth rate is now at -64.79%.
  • Its 5 year cash and equivalents growth rate is now at 148.89%.
  • Its 5 year net cashflow from operations growth rate is now at 2.79%.
HTBX's revenue has moved up $2,085,180 over the prior 52 months.

The table below shows HTBX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 2.451063 -22.94841 -29.37858
2021-03-31 2.584734 -21.09049 -27.28981
2020-12-31 2.947969 -22.02136 -26.04974
2020-09-30 4.343893 -15.83093 -22.93477
2020-06-30 3.5006 -14.67511 -20.27776
2020-03-31 3.249922 -14.44278 -20.5942

HTBX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • HTBX has a Quality Grade of D, ranking ahead of 7.24% of graded US stocks.
  • HTBX's asset turnover comes in at 0.018 -- ranking 372nd of 677 Pharmaceutical Products stocks.
  • TXMD, ENTA, and GILD are the stocks whose asset turnover ratios are most correlated with HTBX.

The table below shows HTBX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.018 1 -0.270
2021-03-31 0.023 1 -0.309
2020-12-31 0.034 1 -0.411
2020-09-30 0.069 1 -0.602
2020-06-30 0.096 1 -1.360
2020-03-31 0.110 1 -2.217

HTBX Price Target

For more insight on analysts targets of HTBX, see our HTBX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $4.75 Average Broker Recommendation 1.5 (Moderate Buy)

HTBX Stock Price Chart Interactive Chart >

Price chart for HTBX

HTBX Price/Volume Stats

Current price $6.12 52-week high $17.00
Prev. close $6.27 52-week low $5.22
Day low $6.10 Volume 164,700
Day high $6.29 Avg. volume 1,269,529
50-day MA $6.44 Dividend yield N/A
200-day MA $6.98 Market Cap 155.43M

Heat Biologics, Inc. (HTBX) Company Bio


Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Morrisville, NC.


HTBX Latest News Stream


Event/Time News Detail
Loading, please wait...

HTBX Latest Social Stream


Loading social stream, please wait...

View Full HTBX Social Stream

Latest HTBX News From Around the Web

Below are the latest news stories about Heat Biologics Inc that investors may wish to consider to help them evaluate HTBX as an investment opportunity.

Heat Biologics CEO to Present at the Cantor Fitzgerald Global Healthcare Conference on September 29th

DURHAM, N.C., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (Nasdaq: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced that Jeff Wolf, Chief Executive Officer of Heat Biologics, will be presenting at the Cantor Fitzgerald Global Healthcare Conference being held virtually between September 27-30, 2021.

Intrado Digital Media | September 15, 2021

Heat Biologics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

No summary available.

Heat Biologics | September 9, 2021

HTBX: September Business Update

By John Vandermosten, CFA NASDAQ:HTBX READ THE FULL HTBX RESEARCH REPORT Business Update Conference Call Heat Biologics, Inc. (NASDAQ:HTBX) hosted a business update conference call on September 2, 2021 to discuss the status of active programs, objectives of new subsidiaries, and longer term opportunities for the company. The replay for the call is available through September 16 th . New

Yahoo | September 8, 2021

Heat Biologics to Provide Corporate Update

No summary available.

Heat Biologics | August 30, 2021

Heat Biologics Unveils Skunkworx Bio, New Drug Discovery Subsidiary

Developing a new era of precision medicines using a unique and proprietary drug discovery platform Developing a new era of precision medicines using a unique and proprietary drug discovery platform

Intrado Digital Media | August 26, 2021

Read More 'HTBX' Stories Here

HTBX Price Returns

1-mo -9.47%
3-mo -15.24%
6-mo -13.56%
1-year -31.70%
3-year -56.72%
5-year -93.93%
YTD 14.18%
2020 61.20%
2019 -51.53%
2018 -74.41%
2017 -55.47%
2016 -64.75%

Continue Researching HTBX

Here are a few links from around the web to help you further your research on Heat Biologics Inc's stock as an investment opportunity:

Heat Biologics Inc (HTBX) Stock Price | Nasdaq
Heat Biologics Inc (HTBX) Stock Quote, History and News - Yahoo Finance
Heat Biologics Inc (HTBX) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.9192 seconds.